SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Events
Featured Reports
Apr 28, 2021
2020 Proxy Statement
Mar 12, 2021
2020 Annual Report

Press Releases

24 Nov
Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia
-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions- WATERTOWN, Mass. , Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop
11 Nov
Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference
WATERTOWN, Mass. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
09 Nov
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform- -Reported topline data from SEL-399 (empty AAV8 capsid in combination with ImmTOR); Selecta intends continued expansion of ImmTOR platform across gene therapy pipeline-
08 Nov
Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy
- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 - - With co-administration of AAV8 empty capsids and ImmTOR, Selecta observed dose-dependent response to ImmTOR with a safety profile in line with prior human studies - -
Stock Information
Stock Information
Information Request
Information Request
Financial Information
Financial Information
FAQ
FAQ